Familial Aggregation and ABO Blood Groups and COVID-19 Severity Among Hospitalized Patients

Abstract

Abstract Background Planning effective preventive and control measures requires understanding of the variability in the severity of infectious illnesses and factors determining susceptibility. The present study aimed to assess the association between familial susceptibility and ABO blood group with COVID-19 disease severity and adverse outcomes. Methods The present study was a retrospective investigation that was carried out at a tertiary care hospital with a bed capacity of 560 in the state of Kerala, India. A structured questionnaire was used to extract demographic and clinical characteristics from screened records. The study participants were stratified into 2 distinct groups based on the severity of their illness: mild to moderate and severe. Familial aggregation was operationally defined as the occurrence of COVID-19 diagnosis in any first-degree relative. Results A total of 362 hospitalized patients with confirmed COVID-19 infection were included in the analysis. Among them 62 (17.1%) were categorized as severe COVID-19 and 300 (82.9%) were categorized as mild to moderate COVID-19. Binary logistic regression analysis showed that the odds of sever COVID-19 disease was significantly higher among patients with familial aggregation (odds ratio, 2.47; 95% confidence interval, 2.12–2.85) and with non-O blood group (odds ratio, 2.21; 95% confidence interval, 2.01–2.56). Conclusions The findings of our study highlight the significance of familial aggregation and ABO blood group as crucial factors in determining the severity of COVID-19 disease. Comprehending the interrelationship between these variables and the genetic makeup of the host may hold significance in prognosticating the gravity of COVID-19 consequences.